DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 766,566 shares of the medical device company's stock after buying an additional 196,873 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.20% of DexCom worth $59,616,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA grew its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity

In other news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock valued at $8,044,178 in the last ninety days. Insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $3.41 on Thursday, hitting $70.27. 1,780,935 shares of the company were exchanged, compared to its average volume of 4,141,767. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock's 50 day moving average price is $73.83 and its 200 day moving average price is $76.60. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The firm has a market capitalization of $27.55 billion, a P/E ratio of 49.15, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on DXCM shares. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.